Human Leukocyte Antigen Class I Gene Mutations in Cervical Cancer
BACKGROUND: Various mechanisms contribute to the loss of human leukocyte antigen (HLA) class I expression that is frequently observed in cancers. Although some single allele losses have been ascribed to mutations in HLA class I genes, direct evidence for this phenomenon in vivo is still lacking. Thu...
Saved in:
Published in: | JNCI : Journal of the National Cancer Institute Vol. 91; no. 19; pp. 1669 - 1677 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
Cary, NC
Oxford University Press
06-10-1999
Oxford Publishing Limited (England) |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | BACKGROUND: Various mechanisms contribute to the loss of human leukocyte antigen (HLA) class I expression that is frequently observed in cancers. Although some single allele losses have been ascribed to mutations in HLA class I genes, direct evidence for this phenomenon in vivo is still lacking. Thus, we investigated whether HLA class I gene mutations could account for the loss of allele-specific expression in cervical carcinomas. METHODS: We used polymerase chain reaction-based techniques, including sequencing, oligonucleotide hybridization, and microsatellite analysis, to identify HLA class I gene defects in two tumor-derived cell lines and to confirm the presence of these defects in the original tumors. RESULTS: In one tumor, in exon 2 of the HLA-B15 gene, a four-nucleotide insertion resulted in a stop codon in exon 3. In the other tumor, in two duplicated copies of the HLA-A24 gene, single-point mutations resulted in stop codons in exons 2 and 5. CONCLUSIONS: To our knowledge, this is the first report of HLA class I gene mutations identified in primary tumors that lead to loss of allelic expression in tumor cells. Such tumor-specific mutations may permit the cell to escape HLA class I-restricted cytotoxic T-cell responses. |
---|---|
Bibliography: | local:1669.sgm Correspondence to: Louise A. Koopman, M.Sc., Department of Pathology, L1-Q/P1-40, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands (e-mail: L.A.Koopman@pathology.medfac.leidenuniv.nl). ark:/67375/HXZ-V85R3TNG-X istex:571D982273DD196EDD6724105B74E3ED6E519023 PII:1460-2105 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0027-8874 1460-2105 |
DOI: | 10.1093/jnci/91.19.1669 |